Option chain shows key data for Cyclacel Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Option Chain

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Wall-Street-ai7-1

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRNC

CTCX

CYCC

DOGZ

IDAI

NITO

Nasdaq Surges Over 1%; Cerence Shares Spike Higher

vaccine-4892059

Cyclacel Pharmaceuticals shares are trading higher by 77% during Friday&#39;s session. The company announced a securities purchase agreement with investor David Lazar.

Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing

Wall Street Bulls

Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cycclone Inc

Financing

Press Releases

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

General

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Management

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Earnings

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCCP

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Ainos

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

Genprex

HCW Biologics

Immuron Limited - American Depositary Shares

Immuron

IN8bio

Kairos Pharma

Moleculin Biotech

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Portage Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell